Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

Pamela S. Becker, MD, PhD, Sylvia Chien, Mikhail Roshal, MD, PhD, Brent Wood, MD, PhD, Elihu Estey, MD, Thalia Papayannopoulou, MD, Xin Zhao, MD, Soumit Basu, MD, PhD, Mark McGrath, Kenneth Kopecky, PhD, Frederick R Appelbaum, MD

Blood (2009) 114 (22): 2658.

https://doi.org/10.1182/blood.V114.22.2658.2658

Published: 2009

Journal Articles

Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Patients with Acute Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Zeev Estrov, MD, Wanlong Ma, Chen-Hsiung Yeh, Anthony Sferruzza, PhD, Elihu Estey, MD, Maher Albitar, M.D.

Blood (2009) 114 (22): 3104.

https://doi.org/10.1182/blood.V114.22.3104.3104

Published: 2009

Journal Articles

Significant Association Between Promoter Polymorphism of the Erythropoietin Gene and Myelodysplastic Syndrome.

Wanlong Ma, Hagop Kantarjian, MD, Ke Zhang, XI Zhang, Xiuqiang Wang, Zhong Zhang, MD, PhD, Chen-Hsiung Yeh, Anthony Sferruzza, PhD, Susan O'Brien, Elihu Estey, MD, Maher Albitar, M.D.

Blood (2009) 114 (22): 3825.

https://doi.org/10.1182/blood.V114.22.3825.3825

Published: 2009

Journal Articles

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Barry E Storer, PhD, Frederick R Appelbaum, MD

Blood (2009) 114 (22): 2068.

https://doi.org/10.1182/blood.V114.22.2068.2068

Published: 2009

Journal Articles

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pamela S. Becker, MD, PhD, Elihu Estey, MD, Stephen Petersdorf, MD, Paul C. Hendrie, MD, PhD, John M. Pagel, MD, PhD, Derek Stirewalt, MD, Andrei Shustov, MD, Barry E. Storer, PhD, Frederick R. Appelbaum, MD

Blood (2008) 112 (11): 2964.

https://doi.org/10.1182/blood.V112.11.2964.2964

Published: 2008

Journal Articles

Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.

Bing Z. Carter, PhD, Duncan H. Mak, Stephen Morris, Gautam Borthakur, MD, Elihu Estey, MD, Anna L. Byrd, RN, Marina Konopleva, MD, PhD, Hagop M. Kantarjian, MD, Michael Andreeff, MD, PhD

Blood (2008) 112 (11): 1943.

https://doi.org/10.1182/blood.V112.11.1943.1943

Published: 2008

Journal Articles

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Apostolia-Maria Tsimberidou, MD, PhD, Elihu Estey, MD, Maher Albitar, MD, Sijin Wen, MS, Mark Brandt, BS, Sherry Pierce, RN, Hagop Kantarjian, MD, Razelle Kurzrock, MD

Blood (2007) 110 (11): 4263.

https://doi.org/10.1182/blood.V110.11.4263.4263

Published: 2007

Journal Articles

Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.

Gautam Borthakur, MD, Hagop Kantarjian, MD, Guillermo Garcia-Manero, MD, Sherry Pierce, RN, Elihu Estey, MD

Blood (2007) 110 (11): 4382.

https://doi.org/10.1182/blood.V110.11.4382.4382

Published: 2007

Journal Articles

Untreated Patients with Acute Myeloid Leukemia, Age 50–59 Years and Performance Status 2 Should Be as Eligible for Targeted Therapy as Older Patients.

Apostolia M. Tsimberidou, MD, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Sherry Pierce, RN, Emil J. Freireich, MD, Elihu Estey, MD

Blood (2007) 110 (11): 2864.

https://doi.org/10.1182/blood.V110.11.2864.2864

Published: 2007

Journal Articles

Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia.

John Delmonte, Jr., MD, Hagop M. Kantarjian, MD, Elihu Estey, MD, Farhad Ravandi, MD, Gautam Borthakur, MD, Jan Burger, MD/PhD, Sherry Pierce, Jorge Cortes, MD

Blood (2007) 110 (11): 3505.

https://doi.org/10.1182/blood.V110.11.3505.3505

Published: 2007

Journal Articles

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Paul M. Armistead, MD, PhD, Marcos de Lima, MD, Sherry Pierce, RN, Wei Qiao, PhD, Xuemei Wang, PhD, Peter Thall, PhD, Sergio Giralt, MD, Richard Champlin, MD, Elihu Estey, MD

Blood (2007) 110 (11): 329.

https://doi.org/10.1182/blood.V110.11.329.329

Published: 2007

Journal Articles

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

Dushyant Verma, MD, FACP, Deborah Thomas, MD, Susan O’Brien, MD, Stefan Faderl, MD, Charles Koller, MD, Sherry Pierce, RN, Elihu Estey, MD, Guillermo Garcia-Manero, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2007) 110 (11): 2832.

https://doi.org/10.1182/blood.V110.11.2832.2832

Published: 2007

Journal Articles

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Elihu Estey, MD, Zhuoxin Sun, MD, Jacob Rowe, MD, Stefan Faderl, MD, Peter Cassileth, MD, George Sartiano, MD, Anthony Tartaglia, MD, Guillermo Garcia-Manero, MD, Larry Cripe, MD, John Bennett, MD, Hagop Kantarjian, MD, Martin Tallman, MD

Blood (2007) 110 (11): 298.

https://doi.org/10.1182/blood.V110.11.298.298

Published: 2007

Journal Articles

Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

Gautam Borthakur, MD, Nitin Jain, Hagop Kantarjian, MD, E. Lin, MS, Farhad Ravandi, MD, Sherry Pierce, RN, Elihu Estey, MD

Blood (2007) 110 (11): 2856.

https://doi.org/10.1182/blood.V110.11.2856.2856

Published: 2007

Journal Articles

Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.

Masamitsu Yanada, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Hagop Kantarjian, MD, Elihu Estey, MD

Blood (2007) 110 (11): 1852.

https://doi.org/10.1182/blood.V110.11.1852.1852

Published: 2007

Journal Articles

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Gloria Mattiuzzi, MD, Jorge Cortes, MD, Deborah Blamble, PHDP, Elihu Estey, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 1824.

https://doi.org/10.1182/blood.V110.11.1824.1824

Published: 2007

Journal Articles

Use of Post-Treatment Clinical Data To Predict Response to Decitabine.

Elihu Estey, MD, J.-P. Issa, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 1448.

https://doi.org/10.1182/blood.V110.11.1448.1448

Published: 2007

Journal Articles

Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis.

Constantine S. Tam, MBBS, Deborah A. Thomas, MD, Farhad Ravandi, MD, Catherine D. Richardson, RN, MSN, Gautam Borthakur, MD, Jan A. Burger, MD, Elihu Estey, MD, Hagop Kantarjian, MD, Srdan Verstovsek, MD

Blood (2007) 110 (11): 3552.

https://doi.org/10.1182/blood.V110.11.3552.3552

Published: 2007

Journal Articles

Exclusion from Acute Myeloid Leukemia (AML) Clinical Trials of Patients Unlikely To Respond.

Apostolia-Maria Tsimberidou, MD, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Emil J. Freireich, MD, Elihu Estey, MD

Blood (2007) 110 (11): 2867.

https://doi.org/10.1182/blood.V110.11.2867.2867

Published: 2007

Journal Articles

Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML).

Mikkael A. Sekeres, MD, MS, Paul Elson, Xuemei Wang, Matt Kalaycio, MD, Anjali Advani, MD, Edward Copelan, MD, Stefan Faderl, MD, Hagop Kantarjian, MD, Elihu Estey, MD

Blood (2007) 110 (11): 598.

https://doi.org/10.1182/blood.V110.11.598.598

Published: 2007

NARROW

Adhesion Receptor Expression by Acute Myeloid Leukemia (AML) Bone Marrow Derived or Circulating Blasts and AML Stem Cells: The Key to Overcoming Chemoresistance.

Clinical Significance of Circulating Ki-67 Protein and Caspase-3 Activity Levels in Patients with Acute Myeloid Leukemia.

Significant Association Between Promoter Polymorphism of the Erythropoietin Gene and Myelodysplastic Syndrome.

G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML).

Phase I Trial of Clofarabine and High Dose Cytarabine with G-CSF Priming (G-CLAC) for Relapsed or Refractory Acute Myeloid Leukemia

Pharmacodynamic Study of Phase 1/2 Trial of the XIAP Antisense Oligonucleotide (AEG35156) in Combination with Chemotherapy in Patients with Relapsed/Refractory AML.

Prognostic Significance of Tissue Necrosis Factor-Alpha in Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes.

Salvage Therapy with Standard Dose Cytarabine Is Appropriate for Patients with Acute Myelogenous Leukemia Refractory to Front-Line Therapy with Hypomethylating Agents.

Untreated Patients with Acute Myeloid Leukemia, Age 50–59 Years and Performance Status 2 Should Be as Eligible for Targeted Therapy as Older Patients.

Single Center Experience with Philadelphia Chromosome-Positive Acute Myeloid Leukemia.

Identifying Relapsed AML Patients Most Likely To Benefit from Allogeneic Stem Cell Transplant: A Statistical Subgroup Analysis.

Therapy Related Acute Myelogenous Leukemia and Myelodysplastic Syndrome in Patients with Acute Lymphoblastic Leukemia Treated with the Hyper-CVAD Regimen.

A 3,239 -Patient Combined Eastern Cooperative Oncology Group (ECOG), M.D. Anderson Cancer Center (MDA) Analysis of the Effect of CR vs. Responses < CR on Long-Term Survival in Newly-Diagnosed AML Treated with Ara-C-Containing Regimens: Implications for Targeted Drug Development.

Survival Is Poorer in Patients with Secondary Core Binding Factor Acute Myelogenous Leukemia Compared with De Novo Core Binding Factor Leukemia.

Kinetics of Bone Marrow Blasts during Remission Induction Course in Acute Myeloid Leukemia: Effect on Complete Remission and Relapse-Free Survival.

Liposomal Amphotericin B IV (LIPO AB) Once Per Week Is Effective in the Prevention of Invasive Fungal Infections (IFI) in Patients (Pts) with Acute Leukemia: Preliminary Analysis of a Randomized Trial.

Use of Post-Treatment Clinical Data To Predict Response to Decitabine.

Phase II Evaluation of Sunitinib Malate, a Multi-Targeted Inhibitor of Receptor Tyrosine Kinases, in Patients with Myelofibrosis.

Exclusion from Acute Myeloid Leukemia (AML) Clinical Trials of Patients Unlikely To Respond.

Time from Diagnosis to Treatment Initiation Predicts Survival in Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only